Psoriasis Clinical Trial

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

View Full Description

Full Description

The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis.

The study will enroll approximately 600 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the following treatment groups in a ratio of 3:1:1 to receive TAK-279, placebo, or apremilast which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

TAK-279
Placebo
Apremilast

This multi-center trial will be conducted worldwide. Participants will go through a screening process to make sure they meet the rules for taking part in the study. This will take up to 35 days. If participants meet the study rules, they will be treated for up to 52 weeks (1 year). There will be a safety follow-up visit 4 weeks after their last day of treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Plaque psoriasis for at least 6 months.
Moderate to severe disease.
Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

Other forms of psoriasis.
History of recent infection.
Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

600

Study ID:

NCT06088043

Recruitment Status:

Recruiting

Sponsor:

Takeda

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 22 Locations for this study

See Locations Near You

Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix Arizona, 85008, United States More Info
Site Contact
Contact
480-562-3610
[email protected]
Dathan Hamann, MD
Principal Investigator
First OC Dermatology - Fountain Valley
Fountain Valley California, 92708, United States More Info
Site Contact
Contact
714-531-2966
[email protected]
Vivian Laquer, MD
Principal Investigator
Center for Dermatology Clinical Research
Fremont California, 94538, United States More Info
Site Contact
Contact
510-797-0140
[email protected]
Sunil Dhawan, MD
Principal Investigator
Driven Research LLC
Coral Gables Florida, 33134, United States More Info
Site Contact
Contact
305-225-0400
[email protected]
Javier Alonso-Llamazares, MD
Principal Investigator
FXM Clinical Research Ft. Lauderdale, LLC
Fort Lauderdale Florida, 33308, United States More Info
Site Contact
Contact
954-368-4406
[email protected]
Igor Chaplik, DO, MD
Principal Investigator
Direct Helpers Research Center
Hialeah Florida, 33012, United States More Info
Site Contact
Contact
305-324-2110
[email protected]
Frank Don, DO
Principal Investigator
FXM Clinical Research Miami, LLC
Miami Florida, 33175, United States More Info
Site Contact
Contact
305-220-5222
[email protected]
Hector Wiltz, MD
Principal Investigator
Renstar Medical Research -21 NE 1st Ave
Ocala Florida, 34470, United States More Info
Site Contact
Contact
352-629-5800
[email protected]
Ashley Cauthen, MD
Principal Investigator
Marietta Dermatology & The Skin Cancer Center - Marietta
Marietta Georgia, 30060, United States More Info
Site Contact
Contact
770-421-2037
[email protected]
Mark Knautz, MD
Principal Investigator
Georgia Skin and Cancer Clinic
Savannah Georgia, 31419, United States More Info
Site Contact
Contact
919-830-4841
[email protected]
Sidney Smith, MD
Principal Investigator
Leavitt Clinical Research
Idaho Falls Idaho, 83404, United States More Info
Site Contact
Contact
208-502-3039
[email protected]
Brandon Miner, DO
Principal Investigator
Arlington Dermatology
Rolling Meadows Illinois, 60008, United States More Info
Site Contact
Contact
847-392-5440
[email protected]
Michael Bukhalo, MD
Principal Investigator
Dawes Fretzin Clinical Research Group LLC
Indianapolis Indiana, 46256, United States More Info
Site Contact
Contact
317-516-5030
[email protected]
Kenneth Dawes, MD
Principal Investigator
Revival Research Corporation - Michigan - ClinEdge - PPDS
Troy Michigan, 48084, United States More Info
Site Contact
Contact
248-564-1485
[email protected]
Ali Moiin, MD
Principal Investigator
Grekin Skin Institute
Warren Michigan, 48088, United States More Info
Site Contact
Contact
586-759-5525
[email protected]
Steven Grekin, DO
Principal Investigator
Henderson Clinical Trials
Henderson Nevada, 89052, United States More Info
Site Contact
Contact
725-218-3236
[email protected]
Vikas Sayal, MD
Principal Investigator
ALLCUTIS Research, LLC.
Portsmouth New Hampshire, 03801, United States More Info
Site Contact
Contact
603-319-8863
[email protected]
Abel Jarell, MD
Principal Investigator
Bexley Dermatology Research - Probity - PPDS
Bexley Ohio, 43209, United States More Info
Site Contact
Contact
614-293-4464
[email protected]
Matthew Zirwas, MD
Principal Investigator
Clinical Research Center of the Carolinas, LLC
Charleston South Carolina, 29407, United States More Info
Site Contact
Contact
843-556-8886
[email protected]
Todd Schlesinger, MD
Principal Investigator
International Clinical Research-Tennessee LLC
Murfreesboro Tennessee, 37130, United States More Info
Site Contact
Contact
615-410-3460
[email protected]
Christina Feser, DO
Principal Investigator
Bellaire Dermatology Associates
Bellaire Texas, 77401, United States More Info
Site Contact
Contact
713-661-4383
[email protected]
Craig Teller, MD
Principal Investigator
Progressive Clinical Research PA - San Antonio
San Antonio Texas, 78213, United States More Info
Site Contact
Contact
210-614-5557
[email protected]
Mark Lee, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

600

Study ID:

NCT06088043

Recruitment Status:

Recruiting

Sponsor:


Takeda

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.